explore -WSS

explore

author：knowledge 2025-09-06 02:05:56 - browse：22

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Inside the culture of fear in the White House science office of Eric Lander

focus

WSS

FDA struggles to regulate food additives, sometimes for decades

Hospital price transparency does save money, advocate argues

Sophia Smith scores twice for US in in 3

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

FAMU bans football players from facility after release of rap video shot in team's locker room

FAMU bans football players from facility after release of rap video shot in team's locker room

focus

explore

focus

Peter Hotez and the public health issue of online harassment

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Supreme Court strikes down use of affirmative action

NIH confirmation hearing shows politicization of research

Peter Hotez and the public health issue of online harassment

FDA approves first blood sugar monitor without finger pricks

United colonoscopy coverage change 'may cost lives,' doctors say

Impact of Dobbs ruling felt at reproductive medicine meeting

DIEP, the 'gold standard' of breast reconstruction, is under threat

Lawmakers consider Medicare pay reforms for doctors

explore

Clinic falsely told dozens they had Alzheimer's, suits say

How climate

UnitedHealth’s board chair also owns a personal investment firm

Hospital price transparency does save money, advocate argues

Clinic falsely told dozens they had Alzheimer's, suits say

First Opinion Podcast: Long Covid needs a new approach

knowledge

focus

entertainment

entertainment